Hepatitis B Virus Infection and Liver Decompensation

Brendon K Luvisa; Tarek I Hassanein

doi:10.1016/j.cld.2016.07.002

Hepatitis B Virus Infection and Liver Decompensation

Clin Liver Dis. 2016 Nov;20(4):681-692. doi: 10.1016/j.cld.2016.07.002.

Authors

Brendon K Luvisa¹, Tarek I Hassanein²

Affiliations

¹ Southern California Research Center, Coronado, CA 92118, USA.
² Southern California Research Center, Coronado, CA 92118, USA; University of California, San Diego School of Medicine, San Diego, CA, USA. Electronic address: thassanein@livercenters.com.

PMID: 27742007
DOI: 10.1016/j.cld.2016.07.002

Abstract

The goal in patients with immune active hepatitis B virus (HBV) infection is to significantly suppress viral replication and prevent progression of fibrosis to cirrhosis and liver decompensation and decrease the incidence of hepatocellular carcinoma. This is achievable by the highly active antivirals, entecavir and tenofovir, which are considered first-line therapy in most patients with immune active hepatitis C virus and after liver transplantation to prevent HBV recurrence. Patients with decompensated cirrhosis should be referred for liver transplantation and treated with first-line antivirals as early as possible, with the goal of achieving complete viral suppression in the shortest time possible.

Keywords: Hepatitis B virus; Hepatocellular carcinoma; Highly active antivirals; Liver decompensation; Liver support system.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
DNA, Viral / analysis
Disease Progression
End Stage Liver Disease* / epidemiology
End Stage Liver Disease* / etiology
End Stage Liver Disease* / prevention & control
Global Health
Hepatitis B / complications
Hepatitis B / drug therapy*
Hepatitis B / virology
Hepatitis B virus / genetics*
Humans
Incidence
Liver Neoplasms* / epidemiology
Liver Neoplasms* / etiology
Liver Neoplasms* / prevention & control
Virus Replication / drug effects*

Substances

Antiviral Agents
DNA, Viral